HIV integrase inhibitors

US7902182B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• B. Narasimhulu Naidu · Durham, US
• Margaret E. Sorenson · Swedesburg, US
• Yasutsugu Ueda · Clinton, US
• John D. Matiskella · Wallingford, US
• Michael A. Walker · Durham, US

Key dates

• Filing date: Nov 10, 2006
• Grant date: Mar 8, 2011
• Expiry date: May 13, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D239/70
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.